StockNews.AI
ALDX
StockNews.AI
138 days

BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm

1. ALDX shares dropped nearly 75% following an FDA rejection. 2. The FDA cited concerns over its drug reproxalap's efficacy. 3. Block & Leviton is investigating potential securities law violations. 4. Investors losing money may contact Block & Leviton for recovery. 5. Whistleblowers with information can report to the SEC for rewards.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The severe drop in stock price and regulatory issues indicate a loss of investor confidence, similar to other firms facing FDA rejections which often lead to prolonged negative outlooks.

How important is it?

The investigation by Block & Leviton adds to the negative sentiment, directly impacting ALDX's future pricing and investor trust.

Why Short Term?

The immediate reaction from investors shows rapid negative sentiment that might take time to recover.

Related Companies

ALDXVRTXAKBA
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) for potential securities law violations. Investors who have lost money in their Aldeyra Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/aldx. What is this all about? Shares of Aldeyra Therapeutics, Inc. fell nearly 75% in intraday trading, after the company disclosed that the FDA issued a second Complete Response Letter (CRL) for reproxalap, Aldeyra's lead dry eye disease drug candidate. The FDA's CRL cited a failure to demonstrate efficacy for reproxalap and flagged concerns with the design of Aldeyra’s most recent trial, including differences in baseline symptom scores that may have impacted the reliability of their trial results. Block & Leviton is investigating whether Aldeyra adequately disclosed the risks related to its clinical data and regulatory approval process. Who is eligible? Anyone who purchased Aldeyra Therapeutics, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more. What is Block & Leviton doing? Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money. What should you do next? If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at shareholders@blockleviton.com, or by phone at (888) 256-2510. Whistleblower? If you have non-public information about Aldeyra Therapeutics, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at shareholders@blockleviton.com or by phone at (888) 256-2510. Why should you contact Block & Leviton? Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email shareholders@blockleviton.com with any questions. This notice may constitute attorney advertising. CONTACT:BLOCK & LEVITON LLP260 Franklin St., Suite 1860Boston, MA 02110Phone: (888) 256-2510Email: shareholders@blockleviton.com 

Related News